(Reuters) – British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.
The drug, known as Gepotidacin, is being developed for use in adults and adolescents for the sexually transmitted infection that sees about 82 million new cases globally each year.
(Reporting by Prerna Bedi and Eva Mathews in Bengaluru)
